|Chemical and physical data|
|Molar mass||379.504 g·mol−1|
|3D model (JSmol)|
1P-LSD or 1-propionyl-lysergic acid diethylamide is a psychedelic drug of the lysergamide class that is a derivative and functional analogue of LSD and a homologue of ALD-52. It has been sold online as a designer drug since 2015. It modifies the LSD molecule by adding a propionyl group to the nitrogen molecule of LSD's indole.
In mice, 1P-LSD produces LSD-like effects with 38% the potency of LSD and it is therefore classed as a serotonergic hallucinogen. However, 1P-LSD itself is unable to bind to the serotenergic 5-HT2A receptors. But since LSD is detected when 1P-LSD is incubated in human serum, 1P-LSD may act, at least in part, as a prodrug for LSD.
The effects profile of 1P-LSD is not well defined in the scientific literature. It is generally thought to be comparable to that of LSD. Many anecdotal reports indicate that 1P-LSD has a slightly shorter duration than LSD in humans, with the majority of users stating that they cannot distinguish the qualitative effects of 1P-LSD from LSD.
1P-LSD is illegal in Belgium since 26 September 2017.
1P-LSD is illegal in Denmark.
1P-LSD is illegal in Finland.
1P-LSD is illegal in Germany as part of the NpSG.
1P-LSD is illegal in Estonia since 4 June 2017.
1P-LSD is illegal in Japan since 18 April 2016.
1P-LSD is illegal in Latvia. Although it isn't specifically scheduled, it is controlled as an LSD structural analog due to an amendment made on June 1, 2015.
1P-LSD is illegal in Lithuania.
1P-LSD is illegal in Norway.
1P-LSD is illegal to produce or sell in Romania. It is not included directly in the list of controlled substances, but it is included in an analogue act. However, it is not, as of yet, classified as illegal to use.
Public Health Agency of Sweden added 1P-LSD as health hazard under the act Act on the Prohibition of Certain Goods Dangerous to Health (SFS 1999:42) in Sweden as of January 26, 2016, published in SFS 2015:997 listed as N,N-dietyl-6-metyl-1-propionyl-9,10-didehydroergolin-8-karboxamid (1P-LSD).
1P-LSD is illegal in Switzerland.
While 1P-LSD is not controlled at the federal level in the United States, it is possible that 1P-LSD could be considered as an analogue of LSD, in which case trade or possession with intent for human consumption could be prosecuted under the Federal Analogue Act.
- "Philtre Bulletin Issue 5" (PDF). WEDINOS. March 2015. Retrieved 28 July 2015.
- Max Daly (27 July 2015). "Why Young Brits Are Taking So Much LSD and Ecstasy". Vice. Retrieved 11 August 2015.
- "Newer Unregulated Drugs" (PDF). KFx. April 2015. Retrieved 13 August 2015.
- Matthew Speiser (11 August 2015). "A handful of dangerous new legal drugs has public health experts worried". Business Insider UK. Retrieved 13 August 2015.
- "1P-LSD". New Synthetic Drugs Database.
- Joseph J. Palamar; Patricia Acosta; Scott Sherman; Danielle C. Ompad; Charles M. Cleland (June 2016). "Self-reported use of novel psychoactive substances among attendees of electronic dance music venues". The American Journal of Drug and Alcohol Abuse. 42 (6): 624–632. doi:10.1080/00952990.2016.1181179. PMC 5093056. PMID 27315522.
- Simon D. Brandt; Pierce V. Kavanagh; Folker Westphal; Alexander Stratford; Simon P. Elliott; Khoa Hoang; Jason Wallach; Adam L. Halberstadt (October 2015). "Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD)". Drug Testing and Analysis. 8 (9): 891–902. doi:10.1002/dta.1884. PMC 4829483. PMID 26456305.
- Jose (15 October 2015). "Is 1P-LSD A Prodrug To LSD?". Detect-Kit. Archived from the original on 2015-10-15. Retrieved 15 October 2015. Cite uses deprecated parameter
- P. Linda; A. Stener; A. Cipiciani; G. Savelli (January–February 1983). "Hydrolysis of amides. Kinetics and mechanism of the basic hydrolysis of N-acylpyrroles, N-acylindoles and N-acylcarbazoles". Journal of Heterocyclic Chemistry. 20 (1): 247–248. doi:10.1002/jhet.5570200154.
- Fabrizio Schifano; Laura Orsolini; Duccio Papanti; John Corkery (June 2016). "NPS: Medical Consequences Associated with Their Intake". Neuropharmacology of New Psychoactive Substances (NPS). Current Topics in Behavioral Neurosciences. 32. pp. 351–380. doi:10.1007/7854_2016_15. ISBN 978-3-319-52442-9. OCLC 643052237. PMID 27272067.
- "Royal decision regarding regulation of sedative substances, psychotropic substances" (PDF). Federal Agency for Medicines and Health Products. 26 September 2017.
- "Lists of euphoriant substances". The Danish Medicines Agency. September 2015.
- "Verordnung zur Änderung der Anlage des Neue-psychoaktive-. Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes" [Regulation amending the Annex to the New Psychoactive Substances Act and Appendices to the Narcotics Act] (in German).
- "Muudatus narkootiliste ja psühhotroopsete ainete I nimekirjas" (in Estonian). Republic of Estonia Agency of Medicines.
- "指定薬物一覧" (PDF) (in Japanese). Ministry of Health, Labour and Welfare.
- "Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem" (in Latvian). Latvijas Republikas tiesību akti.
- "31 Forskrift om narkotika (narkotikaforskriften)" (in Norwegian). Helse- og omsorgsdepartementet. 14 February 2013.
- "Förordning om ändring i förordningen (1999:58) om förbud mot vissa hälsofarliga varor" [Ordinance (1999: 58) on the prohibition of certain dangerous goods] (PDF) (in Swedish).
- "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Der Bundesrat.
- "Introduction to the Federal Controlled Substance Analogue Act". Erowid. January 2001.